Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation.

Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation.

Using a reconstituted mouse prostate organ, the effects on endogenous p53 expression of the ras oncogene or of the ras + myc oncogenes were investigated. In this system the ras gene alone causes mild hyperplasia, but the combination of ras and myc leads to the formation of carcinomas. Surprisingly,...

Bibliografski detalji
Glavni autori:	Lu, X, Park, S, Thompson, T, Lane, D
Format:	Journal article
Jezik:	English
Izdano:	1992

Slični predmeti

Intratumor Heterogeneity of K-Ras and p53 Mutations among Human Colorectal Adenomas Containing Early Cancer
od: Walter Giaretti, i dr.
Izdano: (2000-01-01)

Intratumor Heterogeneity of k-ras and p53 Mutations Among Human Colorectal Adenomas Containing Early Cancer
od: Walter Giaretti
Izdano: (2001-01-01)

Aneuploidy Mechanisms in Human Colorectal Preneoplastic Lesions and Barrett’s Esophagus. Is There a Role for K-Ras and p53 Mutations?
od: Walter Giaretti
Izdano: (1997-01-01)

PCR Bias Toward the Wild-Type k-ras and p53 Sequences: Implications for PCR Detection of Mutations and Cancer Diagnosis
od: R. Barnard, i dr.
Izdano: (1998-10-01)

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
od: Wang, Y, i dr.
Izdano: (2013)

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells.
od: Wang, Y, i dr.
Izdano: (2013)

Amyloid aggregates induced by the p53-R280T mutation lead to loss of p53 function in nasopharyngeal carcinoma
od: Jingzhi Li, i dr.
Izdano: (2024-01-01)

甲状腺癌组织中H-ras 和p53 基因突变
od: 李晓曦　陈国锐　赵国华　赵国强
Izdano: (1997-01-01)

喉癌切缘中eIF4E、p53、ras和c-myc表达与预后的研究
od: 雷文斌, i dr.
Izdano: (2007-01-01)

Gene Therapy with p14/tBID Induces Selective and Synergistic Apoptosis in Mutant Ras and Mutant p53 Cancer Cells In Vitro and In Vivo
od: Robert L. Fine, i dr.
Izdano: (2023-01-01)

P63 and P73 Activation in Cancers with p53 Mutation
od: Bi-He Cai, i dr.
Izdano: (2022-06-01)

p53 Mutations and DNA Ploidy in Colorectal Adenocarcinomas
od: Paola Campomenosi, i dr.
Izdano: (1998-01-01)

Tissue-specific interactions between oncogenic K-ras and the p19A̳r̳f̳_p53 pathway determine susceptibility to transformation
od: Young, Nathan Price
Izdano: (2010)

p53 Immunohistochemistry Patterns Are Surrogate Biomarkers for TP53 Mutations in Gastrointestinal Neuroendocrine Neoplasms
od: Junjie Li, i dr.
Izdano: (2021-01-01)

Searching for a cut-off point for p53 immunohistochemistry as evidence of TP53 mutations
od: Ilay Caliskan, i dr.
Izdano: (2024-03-01)

Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53
od: Lopez, C, i dr.
Izdano: (2000)

RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
od: Ali Sakhdari, i dr.
Izdano: (2020-02-01)

Therapeutic targeting of mutated p53 in acute lymphoblastic leukemia
od: Frank N. van Leeuwen
Izdano: (2020-01-01)

The Significance of p53 and K-ras Immunocytochemical Staining in the Diagnosis of Malignant Biliary Obstruction by Brush Cytology during ERCP
Izdano: (2010-06-01)

DNA as an important target in radiation-induced apoptosis of MYC and MYC plus RAS transfected rat embryo fibroblasts.
od: Ayene, I, i dr.
Izdano: (2000)

Structural basis of p53 inactivation by cavity-creating cancer mutations and its implications for the development of mutant p53 reactivators
od: Dimitrios-Ilias Balourdas, i dr.
Izdano: (2024-06-01)

Semiquantitative Chemiluminescent Detection of UV-B-Induced Point Mutations in the p53 Tumor-Suppressor Gene
od: Wilfried Siefken, i dr.
Izdano: (1999-03-01)

P53 together with ferroptosis: a promising strategy leaving cancer cells without escape
od: Zhan Jianhao, i dr.
Izdano: (2023-12-01)

n-ras and k-ras Mutations Among Some Iraqi Patients with Acute Lymphoblastic Leukemia
od: Wiaam Ahmed Al-Amili, i dr.
Izdano: (2016-10-01)

The relationship of P53 gene mutation with clinicopathological characteristic in breast cancer
od: Amrank, Fitreena Anis
Izdano: (2016)

Monitoring changes in the P53 gene mutation to diagnose oral cancer
od: Thangavel Lakshmipriya, i dr.
Izdano: (2024-06-01)

The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations
od: Anna Hertel, i dr.
Izdano: (2025-02-01)

Validation of Fluorescent SSCP Analysis for Sensitive Detection of p53 Mutations
od: L. Moore, i dr.
Izdano: (2000-05-01)

Exploring the MRI and Clinical Features of P53-Mutated Hepatocellular Carcinoma
od: Weng J, i dr.
Izdano: (2024-08-01)

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
od: Lenos, K, i dr.
Izdano: (2012)

The metastasis-promoting P1597L mutation in PlexinB1 enhances Ras activity
od: Ritu Garg, i dr.
Izdano: (2024-08-01)

Evidence for allosteric effects on p53 oligomerization induced by phosphorylation
od: Muller, Petr, i dr.
Izdano: (2019)

The role of p53 in hypoxia-induced apoptosis
od: Poole, R
Izdano: (2010)

Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation
od: Daowei Yang, i dr.
Izdano: (2024-09-01)

Monitoring ctDNA RAS Mutational Status in Metastatic Colorectal Cancer: A Trial Protocol of RAS-trace and RAS-trace-2 Studies
od: Kozo Kataoka, i dr.
Izdano: (2024-04-01)

Standing at odds: mutated RAS and hematopoietic stem cells
od: Monica Nafria, i dr.
Izdano: (2019-11-01)

Therapeutic inhibition of TRF1 impairs the growth of p53‐deficient K‐RasG12V‐induced lung cancer by induction of telomeric DNA damage
od: María García‐Beccaria, i dr.
Izdano: (2015-05-01)

Peptides That Block RAS-p21 Protein-Induced Cell Transformation
od: Matthew R. Pincus, i dr.
Izdano: (2023-02-01)

Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
od: Cristina Trejo-Solís, i dr.
Izdano: (2024-04-01)

Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma.
od: Kocialkowski, S, i dr.
Izdano: (1995)